Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

6.140 -0.230 (-3.61%)
Streaming Delayed Price Updated: 11:29 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Gibbs Mura Announces a Securities Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR); CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura
From Gibbs Mura
Via Business Wire
Important Notice to Long-Term Shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR); Centene Corporation (NYSE: CNC); DoubleVerify Holdings, Inc. (NYSE: DV); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigating Claims
From Grabar Law Office
Via GlobeNewswire
Levi & Korsinsky Reminds Capricor Therapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Levi &amp; Korsinsky Reminds Capricor Therapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Via TheNewswire.com
Topics Fraud Lawsuit
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: Investors With Large Losses in Capricor Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura
From Gibbs Mura
Via Business Wire
Let's take a look at the stocks that are in motion in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Which stocks are moving on Friday?
Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Capricor Therapeutics Hammered On A Surprise FDA Rejection
The company is currently running another study with results due in the third quarter. 
Via Investor's Business Daily
There are notable gap-ups and gap-downs in today's session.
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock
FDA rejected Capricor's BLA for Deramiocel due to insufficient evidence, requesting more clinical data to support approval for Duchenne therapy. 
Via Benzinga
Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy
The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and... 
Via Stocktwits
Wondering what's happening in today's pre-market session?
The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers and losers noted. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’
The company flagged that 10 of 13 patients in two dosing cohorts received a compromised batch of briquilimab, leading to muted results. 
Via Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.